• Explore /
  • Poster
  • / Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy.

Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy.

Abstract Poster

Authors

Edwin Posadas

Edwin M. Posadas

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA

Edwin M. Posadas , Kim N. Chi , Ronald De Wit , Maja J. De Jonge , Gerhardt Attard , Terence W. Friedlander , Margaret K. Yu , Peter Hellemans , Caly Chien , Charlene Connelly Abrams , Martha Gonzalez , Geralyn Carol Trudel , Vijay Chauhan , Juhui James Jiao , Fred Saad

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02123758

Citation

J Clin Oncol 35, 2017 (suppl 6S; abstract 173)

DOI

10.1200/JCO.2017.35.6_suppl.173

Abstract #

173

Poster Bd #

G2

Abstract Disclosures

Similar Posters

First Author: Edwin M. Posadas

First Author: Simon J. Crabb

First Author: Sumit Kumar Subudhi

First Author: Cora N. Sternberg